Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS12010 in moderate-to-severe rheumatoid arthritis
NCT07377773Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of QLS12010 in rheumatoid arthritis (RA), sponsored by Qilu Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QLS12010
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07377773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377773.